Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to -$52.9 million.

  • Nuvation Bio's Cash from Operations fell 7016.25% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$190.0 million, marking a year-over-year decrease of 9165.02%. This contributed to the annual value of -$130.4 million for FY2024, which is 9178.66% down from last year.
  • Per Nuvation Bio's latest filing, its Cash from Operations stood at -$52.9 million for Q3 2025, which was down 7016.25% from -$48.2 million recorded in Q2 2025.
  • Nuvation Bio's Cash from Operations' 5-year high stood at -$15.0 million during Q4 2023, with a 5-year trough of -$52.9 million in Q3 2025.
  • Over the past 3 years, Nuvation Bio's median Cash from Operations value was -$31.1 million (recorded in 2024), while the average stood at -$31.1 million.
  • Over the last 5 years, Nuvation Bio's Cash from Operations had its largest YoY gain of 1876.88% in 2024, and its largest YoY loss of 20808.44% in 2024.
  • Nuvation Bio's Cash from Operations (Quarter) stood at -$15.0 million in 2023, then tumbled by 208.08% to -$46.3 million in 2024, then fell by 14.24% to -$52.9 million in 2025.
  • Its Cash from Operations was -$52.9 million in Q3 2025, compared to -$48.2 million in Q2 2025 and -$42.6 million in Q1 2025.